1.0ARC Oxfordhttps://www.arcgroup.io/oxfordnataliegelderhttps://www.arcgroup.io/oxford/blog/author/nataliegelder/rich600338<blockquote class="wp-embedded-content" data-secret="wb5aFgJ9a1"><a href="https://www.arcgroup.io/oxford/blog/2025/09/09/omass-therapeutics-partners-with-genentech/">OMass Therapeutics  partners with Genentech to Develop and Commercialise Therapies for Inflammatory Bowel Disease</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.arcgroup.io/oxford/blog/2025/09/09/omass-therapeutics-partners-with-genentech/embed/#?secret=wb5aFgJ9a1" width="600" height="338" title="“OMass Therapeutics  partners with Genentech to Develop and Commercialise Therapies for Inflammatory Bowel Disease” — ARC Oxford" data-secret="wb5aFgJ9a1" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://www.arcgroup.io/oxford/wp-includes/js/wp-embed.min.js </script> https://www.arcgroup.io/oxford/wp-content/uploads/sites/4/2025/09/OMass-Therapeutics-partners-with-Genentech.png1731607ARC Oxford based OMass Therapeutics has entered into an exclusive collaboration and license agreement with Genentech for the rights to develop and commercialise OMass' preclinical oral small molecule program for inflammatory bowel disease.